VAR2 Pharmaceuticals

... is a privately held biotechnology company engaged in the design and development of proprietary therapeutic proteins targeting cancer-specific carbohydrate structures for multiple cancer indications.

About VAR2 Pharmaceuticals

VAR2 Pharmaceuticals is a privately held biotechnology company engaged in the design and development of proprietary therapeutic proteins targeting cancer-specific carbohydrate structures for multiple cancer indications. We have a portfolio of proteins with unique affinity and specificity for these cancer-associated carbohydrates for the development of treatments for cancers where there is no effective therapy, such as sarcoma, triple negative breast cancers and prostate cancer.

The technology is based on groundbreaking discoveries made by researchers at University of Copenhagen, Denmark, in collaboration with partners at University of British Columbia, Canada.

Read more
08 May 2019
Uncategorized
On May 7th, Bloom Burton & Co. announced that VAR2 Pharmaceuticals' co-founder and member of the Board, Prof. Poul Sorensen, is one of the three final nominees to the prestigious 2019 Bloom Burton Award, honouring individuals making the greatest contributions to Canada’s healthcare industry...
05 May 2019
Uncategorized
On May 3rd 2019 Co-founder and Chairman of the Board, Dr. Mads Daugaard, was awarded St. Baldrick’s Foundation Awards One-of-a-Kind Grant to Aid in Childhood Cancer Research Discovery for his work to identify and exploit secondary modifications of proteins as targets for novel ex...
19 September 2018
Uncategorized
It is with great pleasure we can announce that Dr. Nader Al-Nakouzi was awarded The FEBS Journal Best Poster Prize for the poster "Expression and regulation of oncofetal chondroitin sulfate in prostate cancer" at the  Cellular signalling and cancer therapy EMBO workshop in Cavtat...
16 September 2018
Uncategorized
Co-founder and executive Chairman of the Board of directors, Dr. Mads Daugaard, are to present data on VAR2-based immunotherapy in the context of the cancer microenvironemnt at the 9th CDD Conference on Cancer, taking place in London, September 17-19, 2018. The title of the talk is "Targeting o...